181 results
8-K
EX-99.1
IONS
Ionis Pharmaceuticals Inc
21 Dec 23
Other Events
8:27pm
), a systemic, progressive and fatal condition that typically leads to progressive heart failure and often death within three-to-five years from disease
8-K
EX-99.1
ke239mw 3bfjz27
27 Sep 23
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer’s disease and Huntington’s disease
7:05am
8-K
EX-99.1
ufy3 j0vm4evddv1
26 Sep 23
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
7:05am
8-K
EX-99.1
xea2jyrlcti pm9
10 Jul 23
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
7:00am
8-K
EX-99.2
b6px d5t8
6 Jun 23
Ionis announces proposed private placement
4:12pm
8-K
EX-99.1
kgp7z9op1qa8l9
25 Apr 23
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
8:40pm
8-K
EX-99.1
bxygq5
24 Apr 23
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
7:00am
8-K
EX-99.1
4h4ma449c0g8n67oc
21 Jun 22
Other Events
6:03am